Compare Johnson & Johnson (JNJ) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Invesco S&P 500 Momentum ETF — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Invesco S&P 500 Momentum ETF trades at $151.15. The key difference: Johnson & Johnson pays a 2.06% dividend while Invesco S&P 500 Momentum ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | SPMO | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Broad Market / Factor |
52-Week High | $267.24 | $161.66 |
52-Week Low | $172.78 | $107.84 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
SPMO, trading at $151.89 with a 2.15% daily gain, shows strong momentum-driven performance, supported by a bullish technical signal from moving averages and positive media coverage highlighting its 26% returns year-to-date. The ETF's concentrated, tech-heavy portfolio leverages AI growth trends, though key financial ratios like P/E and P/S are not disclosed in the provided data. A dividend of $0.25 is scheduled for June 2026, adding income potential for investors.
The outlook for SPMO remains favorable due to sustained momentum factor strength and institutional interest, but risks include high volatility from sector concentration and potential downturns during market rotations. Investors should weigh the ETF's cost efficiency and historical outperformance against its exposure to tech sector swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
